Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2010

View Archived Issues

alpha2A-Adrenoceptor gene polymorphism and overexpression linked to type 2 diabetes

Prostanoid DP receptor antagonist AMG-853 safe in humans

Bepreve reduces allergen-induced ocular itching, nasal congestion and rhinorrhea in phase III trials

XF-73 and XF-70 active against pathogens relevant to biodefense

Submicron budesonide formulation may innovate pediatric asthma treatment

Vaccination with autologous HIV-1-pulsed DCs feasible in HIV

Janssen presents novel dopamine and serotonin receptor antagonists

Sanofi-aventis claims new cannabinoid CB1 receptor antagonists

Boehringer Ingelheim claims novel EGFR inhibitors

Nabi stockholders approve NicVAX option and license agreement

Capstone continues phase II trial of AZX-100 in keloid scarring

Bristol-Myers Squibb and Allergan enter global agreement on ExonHit's AGN-209323

Final dose level approved in Pluristem's phase I trial of PLX-PAD

Seattle Genetics achieves milestone under antibody-drug conjugate collaboration with Genentech

Enanta nominates EDP-239 as lead development candidate for HCV

FDA approves Novo Nordisk's Norditropin FlexPro prefilled growth hormone pen

NicOx grants Bausch & Lomb worldwide rights to NCX-116

Lilly and Transition Therapeutics enter into licensing and collaboration agreement

Solasia and Kyowa Hakko Kirin license agreement for SP-01 in Asia

Lundbeck and Takeda plan phase III trials of Lu-AA21004 and Lu-AA24530

Pfizer and Medivation report phase III results on Dimebon in Alzheimer's disease

Genzyme and PTC report on phase IIb ataluren trial in nmDBMD

Chiesi identifies novel muscarinic M3 receptor antagonists

Light Sciences Oncology completes enrollment in phase III Aptocine trial in MCRC

Advanced Cell Technology's RPE cells granted FDA orphan drug status / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...